CIP2A and Miyoshi myopathy: In addition, a significant reduction in the expression levels of the cancer inhibitor of protein phosphatase 2A (CIP2A) after treatment with bortezomib–dexamethasone therapy (BD) was associated with an improved prognosis for patients with MM.